Gene · 716
Papers3,534
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
801 to 820 of 3,534
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Let's Get Physical: Flavivirus-Host Protein-Protein Interactions in Replication and Pathogenesis. | Front Microbiol | 2022 | 35308381 | PubTator, text mining | PubMed |
| Epigenetic Activation of lncRNA MIR155HG Mediated by Promoter Hypomethylation and SP1 is Correlated with Immune Infiltration in Glioma. | Onco Targets Ther | 2022 | 35299997 | PubTator, text mining | PubMed |
| Natural antibodies and CRP drive anaphylatoxin production by urate crystals. | Sci Rep | 2022 | 35296708 | PubTator, text mining | PubMed |
| Intertwined pathways of complement activation command the pathogenesis of lupus nephritis. | Transl Res | 2022 | 35296451 | PubTator, text mining | PubMed |
| Immunopathology and Immunotherapy of Inflammatory Skin Diseases. | Immune Netw | 2022 | 35291649 | PubTator, text mining | PubMed |
| Experimental evidence for a high rate of maternal-fetal transmission of dengue virus in the presence of antibodies in immunocompromised mice. | EBioMedicine | 2022 | 35290828 | PubTator, text mining | PubMed |
| A novel 12-gene prognostic signature in breast cancer based on the tumor microenvironment. | Ann Transl Med | 2022 | 35284537 | PubTator, text mining | PubMed |
| Role of Complement System in Kidney Transplantation: Stepping From Animal Models to Clinical Application. | Front Immunol | 2022 | 35281019 | PubTator, text mining | PubMed |
| FDA approves first anti-C1s antibody, targeting innate immunity for rare anaemia. | Nat Rev Drug Discov | 2022 | 35277678 | PubTator, text mining | PubMed |
| A Review of Alpha-1 Antitrypsin Binding Partners for Immune Regulation and Potential Therapeutic Application. | Int J Mol Sci | 2022 | 35269582 | PubTator, text mining | PubMed |
| COVIDomics: The Proteomic and Metabolomic Signatures of COVID-19. | Int J Mol Sci | 2022 | 35269564 | PubTator, text mining | PubMed |
| Activation of Complement Components on Circulating Blood Monocytes From COVID-19 Patients. | Front Immunol | 2022 | 35250994 | PubTator, text mining | PubMed |
| Beyond Systemic Lupus Erythematosus and Anti-Phospholipid Syndrome: The Relevance of Complement From Pathogenesis to Pregnancy Outcome in Other Systemic Rheumatologic Diseases. | Front Pharmacol | 2022 | 35242041 | PubTator, text mining | PubMed |
| Urinary detection of early responses to checkpoint blockade and of resistance to it via protease-cleaved antibody-conjugated sensors. | Nat Biomed Eng | 2022 | 35241815 | PubTator, text mining | PubMed |
| Complement Activation via the Lectin and Alternative Pathway in Patients With Severe COVID-19. | Front Immunol | 2022 | 35237273 | PubTator, text mining | PubMed |
| Discoidin Domain Receptor 1, a Potential Biomarker and Therapeutic Target in Hepatocellular Carcinoma. | Int J Gen Med | 2022 | 35237068 | PubTator, text mining | PubMed |
| Contact and intrinsic coagulation pathways are activated and associated with adverse clinical outcomes in COVID-19. | Blood Adv | 2022 | 35235941 | PubTator, text mining | PubMed |
| The EPICC Family of Anti-Inflammatory Peptides: Next Generation Peptides, Additional Mechanisms of Action, and In Vivo and Ex Vivo Efficacy. | Front Immunol | 2022 | 35222367 | PubTator, text mining | PubMed |
| Integrative analysis prioritizes the relevant genes and risk factors for chronic venous disease. | J Vasc Surg Venous Lymphat Disord | 2022 | 35218958 | PubTator, text mining | PubMed |
| Quantitative Visualization of the Interaction between Complement Component C1 and Immunoglobulin G: The Effect of CH1 Domain Deletion. | Int J Mol Sci | 2022 | 35216207 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/716/papers?page=41